Nicolas Leduc1, Vincent Atallah2, Moustapha Agossou3, Vincent Vinh-Hung4,5, Mathieu Orre4, Paul Sargos4, Vincent Molinie6. 1. Radiation Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33800, Bordeaux, France. nicolas.leduc.mail@gmail.com. 2. Radiation Oncology, Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France. 3. Pneumology, Centre Hospitalier de Martinique, La Meynard, 97200, Le Lamentin, France. 4. Radiation Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33800, Bordeaux, France. 5. Radiation Oncology, Centre Hospitalier de Martinique, La Meynard, 97200, Le Lamentin, France. 6. Pathology, Centre Hospitalier de Martinique, La Meynard, 97200, Le Lamentin, France.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide. Shorter survival has been repeatedly reported for patients of African ancestry. Multivariate analysis demonstrated that this gap could be a consequence of socio-economic disparities instead of genetic specificities. However, those results were obtained in a pre-targeted therapies era and the effect of tyrosine kinase inhibitors targeting EGFR are not known in this population. OBJECTIVE: In this French West Indies study, we report overall survival (OS) in a frequently mutated population treated for lung adenocarcinoma within an equal-access healthcare system. PATIENTS AND METHODS: Clinical, demographic, survival, and treatment data have been retrospectively assessed for all patients diagnosed with lung adenocarcinoma in the islands of Martinique and Guadeloupe between 2013 and 2015. RESULTS: Two hundred and forty-one patients (82% African-Caribbean) were included. EGFR mutations were detected in 37% of all tumor specimens and were associated with non-smoker status in multivariate analysis. Median OS was 16.2 months. For patients with advanced disease, median OS was 11.5 months, depending on EGFR mutation (23 vs. 8.3 months for non-mutated patients, p = 0.0012). There was no difference in survival according to ethnicity or island. In multivariate analysis, performance status (PS) and EGFR mutation were the only independent prognostic factors. CONCLUSIONS: Despite a higher frequency of EGFR mutations in African-Caribbean patients, ethnicity was not an independent factor of OS in lung adenocarcinoma. Lower initial PS in this mainly non-smoking African-Caribbean population may explain the absence of a difference in OS.
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide. Shorter survival has been repeatedly reported for patients of African ancestry. Multivariate analysis demonstrated that this gap could be a consequence of socio-economic disparities instead of genetic specificities. However, those results were obtained in a pre-targeted therapies era and the effect of tyrosine kinase inhibitors targeting EGFR are not known in this population. OBJECTIVE: In this French West Indies study, we report overall survival (OS) in a frequently mutated population treated for lung adenocarcinoma within an equal-access healthcare system. PATIENTS AND METHODS: Clinical, demographic, survival, and treatment data have been retrospectively assessed for all patients diagnosed with lung adenocarcinoma in the islands of Martinique and Guadeloupe between 2013 and 2015. RESULTS: Two hundred and forty-one patients (82% African-Caribbean) were included. EGFR mutations were detected in 37% of all tumor specimens and were associated with non-smoker status in multivariate analysis. Median OS was 16.2 months. For patients with advanced disease, median OS was 11.5 months, depending on EGFR mutation (23 vs. 8.3 months for non-mutated patients, p = 0.0012). There was no difference in survival according to ethnicity or island. In multivariate analysis, performance status (PS) and EGFR mutation were the only independent prognostic factors. CONCLUSIONS: Despite a higher frequency of EGFR mutations in African-Caribbean patients, ethnicity was not an independent factor of OS in lung adenocarcinoma. Lower initial PS in this mainly non-smoking African-Caribbean population may explain the absence of a difference in OS.
Authors: A William Blackstock; James E Herndon; Electra D Paskett; Antonius A Miller; Christopher Lathan; Harvey B Niell; Mark A Socinski; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2005-12-19 Impact factor: 44.544
Authors: J Matthew Reinersman; Melissa L Johnson; Gregory J Riely; Dhananjay A Chitale; Anthony D Nicastri; Gerald A Soff; Ann G Schwartz; Camelia S Sima; Getinet Ayalew; Christopher Lau; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: Haiying Cheng; H Dean Hosgood; Lei Deng; Kenny Ye; Christopher Su; Janaki Sharma; Yuanquan Yang; Balazs Halmos; Roman Perez-Soler Journal: Clin Lung Cancer Date: 2019-07-17 Impact factor: 4.785
Authors: Nicholas T Gimbrone; Bhaswati Sarcar; Edna R Gordian; Jason I Rivera; Christian Lopez; Sean J Yoder; Jamie K Teer; Eric A Welsh; Alberto A Chiappori; Matthew B Schabath; Gary W Reuther; Julie Dutil; Miosotis Garcia; Ronald Ventosilla-Villanueva; Luis Vera-Valdivia; Alejandro Yabar-Berrocal; Rodrigo Motta-Guerrero; Pedro G Santiago-Cardona; Teresita Muñoz-Antonia; W Douglas Cress Journal: J Thorac Oncol Date: 2017-09-11 Impact factor: 15.609
Authors: Nicole K Yun; Sherin J Rouhani; Christine M Bestvina; Ethan M Ritz; Brendan A Gilmore; Imad Tarhoni; Jeffrey A Borgia; Marta Batus; Philip D Bonomi; Mary Jo Fidler Journal: Cancers (Basel) Date: 2021-03-20 Impact factor: 6.639